

UBS Virtual Financial Services Conference

Company Participants

- Mark Lyons, Executive Vice President and Chief Financial Officer
- Sabra Purtill, Deputy Chief Financial Officer

Other Participants

- Brian Meredith, Analyst

Presentation

Brian Meredith {BIO 3108204 <GO>}

Good morning, everybody. This is Brian Meredith, I'm the insurance analyst here at UBS. Apologies for all the technical difficulties we've been having here. But we are here for the AIG fireside chat. With us with us today, we've got Mark Lyons, who is the Chief Financial Officer of AIG; Sabra Purtill, the Deputy CFO; and Shelly Singh, who is in charge of Investor Relations for AIG.

Mark has got a couple of quick comments he's going to give, and then I'm going to get right into the fireside chat and the questions. Mark, I'll hand it over to you.

Mark Lyons {BIO 21746221 <GO>}

Great, Brian. And thank you. And so rather than take up a lot of time on pre-comments, especially that it's been cut short a little bit, I'd rather just get into a lot of the questions. I think first of all, thanks again Brian for inviting us for two days. And so we're very, very happy to be here.

We think AIG is very well positioned right now, both from a capital liquidity, subsidiary capital and liquidity perspective as well as taking full advantage of the marketplace on the General Insurance side. But you know, and there's other aspects in the quarter you guys will probably ask about. So, Brian, why don't I just hand it back to you?

Brian Meredith {BIO 3108204 <GO>}

Yes, let's just go ahead. So the first kind of broad question, Mark. So as I look 12 months from now, if you look back on the impact of COVID-19 on the P&C insurance industry and life industries, what do you think the long-term implications are? And how is AIG position to respond?

Mark Lyons {BIO 21746221 <GO>}

FINAL

Well, it's a -- you started off with a crystal ball question. So let's see how good my crystal ball is. So -- well COVID, I think it's clear, has been an accelerant in the -- certainly in the PC marketplace. The market was already, I think, hardening pretty materially. So I deem this an accelerant rather than a cause. AIG, so it's done -- it's lifted all boats, if you will. I think, AIG has been taking maximum advantage of the marketplace and using our breadth and influence and pricing power and so forth to really push things, but really across the board.

But I think the reason we are positioned is because of all those couple of years of hard, hard underwriting changes and redefining appetites, and having a protective reinsurance structure and so forth and so on, that you've heard us talk about before. I think longer term, there's going to be fewer businesses to ensure maybe that's medium term, Brain more than anything else on that.

On the L&R side, whether that affects long-term mortality or not, my -- I mean the actuarial review, assumption review for us will happen throughout the third quarter. But based on what I've seen to-date, I would really believe it's going to affect things long-term. It could be like a blip, but that blip would only come to pass to be elevated, if there's feeling of secondary, longer-term issues associated with COVID. So deep-tissue organ damage, things of that nature that prolong on. But we have to wait and see on that, and I think there'll be some as a result of fewer businesses and other aspects is probably more credit hits coming in across various industries, affecting everyone differently. But I think the net-net is for the medium-term, smaller insurable exposures.

Brian Meredith {BIO 3108204 <GO>}

Great, thanks. So first question is for you, Mark. So COVID-19 charge you took in the quarter was based on claims activity to the first and second quarters. I guess the question is, does this mean that you're likely to have more COVID-19 development here in the next 12-months? And if so where do you think it likely to come from?

Mark Lyons {BIO 21746221 <GO>}

Well I think Sabra and I will ham and egg this a little bit. Let me just start off more conceptually and then I think Sabra can pick it up on some of your more detailed question aspects. But -- so I think from an industry perspective and then I'll give AIG's view on this is -- I think we've been -- we've attempted to be clear on how we've done it, why we've done it. And why we've taken some of the coverage positions that we have. But more broadly, I think there's confusion in the marketplace. Whether it's because of commentary or misinterpretation of commentary or what have you. But the way I look at things and the gray hair that I've amassed over these 40-years, is we have to watch reaching forward and try to reserve today for actions that have not yet occurred. Now I'm talking specifically from a PC perspective.

So why do I bother talk about that. Firstly, it's the responsibility of any property casualty company to reserve as of the balance sheet date for all accidents that have occurred on or prior to that date on an ultimate basis, management's best estimate on an ultimate basis. So at the end of the first quarter, it was for accidents that occurred 3/31 or prior. At

FINAL

the end of the second quarter at 6/30 or prior, whenever you look to first quarter, so forth and so on. So if an accident hasn't occurred yet, you shouldn't reflect it.

And the secondary question would be, why not? And the answer to that is, that's the function of your unearned premium reserve. When you write a \$100 policy on day one, all \$100 are unearned and there is a loss provision in there. Let's say, \$70 loss ratio. So \$70 is associated with accidents that will occur as that exposure earns over time. So to have a loss reserve up for a future occurrence and to have a -- on a premium reserve up for a future occurrence is overlapped, and I don't think any accounting firm would actually ever allow that. So therefore, there's got to be -- it's going to be a misinterpretation. AIG has done what I said, which is we look at all the coverage triggers across all the policy forms that are out there and reflect what's occurred at that point in time.

The reason I say coverage trigger is because, event cancellation is a good example of one where you're noticed earlier, say, then the 6/30 date for a sporting event that's effective in October, let's say, and the decision is made prior to 6/30, as well to cancel by the bank that's the trigger to reflected into your statements as of 6/30 not waiting until the October sporting event. So in that way it reflects and it's consistent with what I just said. But I wanted to clear that up from a -- I think an industry confusion point of view. And with that, I'd say, Sabra to throw in her \$0.02 on this.

Sabra Purtill {BIO 1764408 <GO>}

Yes, sure. So just as a reminder, we put up about \$730 million of COVID-related reserves year-to-date. About 70% of those are for business interruption/property, where we have affirmative coverage for infectious disease, combined with what we put up for contingency and travel. Obviously, as we looked into the second quarter, we did see some reserves that we put out for some other lines, including trade credit, marine, some on casualty, workers' comp, A&H financial lines and then some in our reinsurance business. As we look towards the second half of the year, I would expect that where we would see claims are going to be more on those. What I would call lines that are impacted by the continuing economic crisis as opposed to exposure to the disease itself so trade credit would be an example, for instance.

But, as Mark said, it will reflect the claims activity and events that occur in the third or the fourth quarter. As we believe that we have reserves that are ultimate for what has been reported to us to-date for the -- through the second quarter.

Brian Meredith {BIO 3108204 <GO>}

Great, thank you. So second quarter commercialized pricing AIG, up 16%. I guess the question I have here is one, do you think that continues to accelerate here and for how long? And then on that topic, I know Peter mentioned something about diversification of the commercial lines portfolio, what areas was he referring to?

Mark Lyons {BIO 21746221 <GO>}

Bloomberg Transcript

FINAL

Okay, thanks for that. So I guess a couple of things. As Peter highlights on the calls, the North American commercial segment, reportable segment because that's where most of the changes have occurred, that's where AIG had applied the most surgery. And the reason for that is, that's where it's been a recurring problem for AIG over the years. So I think you leave with where the most correction was made. So the comment about 16% overall, I think you went further to say that it was 21% in commercial North America and 10% internationally. And when you dissect that a little bit further, I think on a prior call, we had talked about the UK already being at 10% and that's continue to accelerate, which means therefore non-UK is less than 10%, but it is increasing in an increasing way.

So we see none of these areas abating, we see no evidence of a debating. And we still had seen things increasing in an increasing way, which I think is good news for everyone. So the reason I brought up the focus on North American commercial Brian, is because what can get lost in the sauce is personal lines business. And when you look at the Japan book in total, for example, that's \$5 billion or \$35 billion, just 15% of the book is basically getting one or two points, which weights and mute the overall results down pretty materially in that regard.

And similarly in lines like action and health and some of the others, which are very predictable year in and year out, but are really aren't a rate issue. So you get these flattening aspects to it. So I wanted to bring that up. In terms of diversification on commercial lines, I think it means more a function of where are the opportunities and therefore where you're going to put time, attention, the capital into those opportunities that are both improving the most rapidly on a relative basis and providing going from red to green or yellow to green, so that there, it hits profitability return standards. So you can accelerate, writing more business there and perhaps keeping more net there. So I think that it really constitutes a mix change that will be different a year from today than it is today.

Brian Meredith {BIO 3108204 <GO>}

Got it, thank you. Next question, so how is commercial lines pricing relative to loss cost trends? You think that with this 16% average price increases margin should be expanding pretty materially from here. And from the second quarter call, you've kind of sounded like you're taking a cautious view on loss trend particularly related to social inflation. Maybe you kind of clarify that a little bit for us?

Mark Lyons {BIO 21746221 <GO>}

Sure, sure. Well, I think some of what we can talk about is really derivative from your prior question actually. But I don't think, I really said much different than I said in the past. I think, I've talked about a range of one or two points on some lines up to upper, knocking on the door of double-digits and some other areas and I think, I pointed out excess casualty and commercial auto in those as well.

So I think it's still within that framework. I think, I've talked about the social inflation in the past on prior calls, as well as -- and there were conferences. So I think it's been fairly consistent with that. So it's really with regard to the expansion of it, and I think it's clear, I

Bloomberg Transcript

FINAL

mean, let's take North America Commercial. You're getting 21% rate increases, I think it's pretty clear, you're going to have margin expansions. I don't think anyone on the call would be thinking we're having 21% loss cost trend at this point and therefore everything stays flat.

So I think it's reasonable to expect that there's going to be margin expansion, but it's not going to be uniformly felt. Going back to our prior discussion, I think it's safer to say in a rank order, there should be a more of that coming through North American Commercial, probably followed by International Commercial and then followed by Personal Lines Areas. So I think that's one kind of view of few.

And secondly, as I kind of alluded to it comes down, you can't just look your rate changes, you have to look at where you are given those rate changes and making sure that's where you want to really invest capital for expansion. And the good part, though is, I think we showed the 6% and 7% increase in net written premium, even with new business down, this shows the strength of the renewal pricing and the retention we've been able to maintain to get that kind of growth. So we've been so defensive, right? Now, we can see some offense coming in on that, and there should be some expansion, but there's still that uncertainty on some aspects of loss cost trends. So I think we talked about this once before that we've been implementing a reserve philosophy that's a lot more let's recognize bad news quickly and good news more slowly. And I think you'll see that reflected on a go-forward basis as well.

Sabra Purtill {BIO 1764408 <GO>}

Yes and Brian, I would just add to that, that really strongly encourage people, particularly because of the impact on personal insurance with the travel business, as well as the syndicate changes that they really need to look at AIG's combined ratios on a segment basis. So for North American Commercial lines for the quarter, we improved 320 basis point, for international it is 500; year-to-date North American Commercials improved by 200 and internationals 180. So clearly, we are building margin in the book on of commercial lines basis.

Brian Meredith {BIO 3108204 <GO>}

Got you. That makes sense, and given where pricing is relative to trend right now, you think that trend should continue to be pretty good?

Sabra Purtill {BIO 1764408 <GO>}

Yes.

Brian Meredith {BIO 3108204 <GO>}

Let's see next question here. Generally, I'm just curious here, how much lower does your combined ratio target need to be today versus let's call it last year at this time? In order to achieve an acceptable return on capital given the interest rate environment with the kind of decline we've seen?

Bloomberg Transcript

FINAL

Mark Lyons {BIO 21746221 <GO>}

Yes, that's a weighted average question. I mean, but I think we can go back to the same kind of commentary, we've done in the last couple. As Sabra just said, that's a function of each segment, with each got it's own characteristics. European trends -- America has 70% of the world's players, right? So -- which -- a catch phrase, I always use which just highlights the fact that things are going to be different in different areas of the world. But we're going to get that margin expansion, when if you guys look at things on the componentry of an ROE and you look at leverage, I think it's pretty clear, when you look at AIG, you're closer to one for one premium to equity ratio on the GI side but you're closer to 3.3, 3.4, I think on invested assets. So the leverage associated our ROE from a change plus or minus in the NII yield, because that's operating view right, that's a total return that's unrealized in there is more impactful. So to the extent that you want to stay even, I don't care what your target is, you're going to have to make up for it more, because of the leverage difference on equity. So it's not proportional.

So if you're going down 100 basis points in ROE, because of reduced NII, you can't just go 100 basis points in the combined ratio, you're going to have to go more. And I think I'm informing you, when you look at those relativities on leverage between invested assets and premium to surplus that guide you, so what it is, you have to do.

Brian Meredith {BIO 3108204 <GO>}

Okay, thanks. That's helpful.

Sabra Purtill {BIO 1764408 <GO>}

Yes. And I would just add, kind of like back of the envelope, I think the way to think about it is, you got to look at the duration of the investment portfolio. Our portfolio in AGI about 3, 3.5 years on duration. So as you lose about -- if you were to lose like 10 basis points of yield on the total portfolio that's maybe 25 to 30 bps on the ROE as opposed to 50 basis points on the combined ratio gives you 30 to 40 bps. So there is obviously a balance. But, as Mark said, it's the impact on the ROE is -- comes much more from the combined ratio improvement, then it would be detracted by the yields.

Brian Meredith {BIO 3108204 <GO>}

Got you. Makes sense.

Mark Lyons {BIO 21746221 <GO>}

The other thing -- I just want to add, Brian, on top of that very, very quick, on Sabra's point, is that you can't talk about a combined ratio without talking about duration. And whether we're of 1.5 year duration in Property Casualty business, let's say assuming captive first, excess work comp, which is 16 to 17 years. And your decision to grow there is more a function of interest rates been pricing, that's going on is -- has to be reflected. And -- and Sabra's point of us being 3.5 years. Let's say an average duration, that's not a huge -- a

monolithic block. There's radically different targets across the board as a function of that duration.

Brian Meredith {BIO 3108204 <GO>}

Yes, great. Okay, let's pivot over to, why Syndicate 2019, been a high topic the last quarter. Maybe you can go through kind of the economics of the transaction of your fee income, a CD commissions. Is this dilutive to earnings? And then another question, how much capital is actually freed up by the transaction, so maybe it's ROE-accretive, but earnings dilutive initially?

Mark Lyons {BIO 21746221 <GO>}

Well, I think, Sabra and I will ham and like this one as well, so we provided some guidance or info to you, which was -- on the last call, which was for the North American Personal Insurance segment, as we reported, which has more than PCG in it, but I know you're trying to help you guys in totality, was \$425 million of net written and \$345 million of net earned is kind of the average by quarter, each quarter that we might expect for 3Q and 4Q. So there's that.

I think secondly, you've got a couple of other consequences associated with that unlike a weighted average impact the loss ratio and expense ratio. And Sabra, I think will go into that a little bit more, but it changes that mix a bit, but it has created some havoc on GOE, if you will, in that area because you have this both out of premium. So you have a depressed premium size, and when you get to some of the businesses like, travel and other things for in there, you're still carrying those GOE costs of underwriting and sales and call centers and whatever else you've been there.

Especially if you expect travel business to not be a long-term sustained hurt industry, and therefore travel insurance supporting the travel industry, and we don't view that as a long-term. We view that as transient, so why would I get rid of all the underwriting -- the systems, everything else that we have associated with it. So that's a distortion that can come in for a while and it could be other noise as well in the balance of the year dealing with, like CAD costs and how that's shared amongst all the capital providers and everything else in there. So, and that noise will oscillate its way out. So as I think -- as I said on the call going into 2021, we're going to have a much different view of us being back to mid to lower '90s in that. And -- but to your point on how does that affect our recognition or our revenue model. Instead of being a 100% underwriter now, we now have a distributed capital model, it was one of the last things, Peter and his team really have the focus on, because we had a lot of bites at the apple on that, you're under any side, because renewals over multiple years. But this continued to be a spike in the concentration risk in CAT. As the old joke goes, rich people like to live together and they like the live on the coast, so you get -- you can't really avoid that concentration risk. So there's other ways to ameliorate, spread that.

So we'll ultimately wind up as you segue into 2021 with about 25% net on that in terms of enjoying the underwriting gain associated with it. And the rest of morphs into more of an MGA model where we have fee income and possibly some reinsurance overrides

associated with that, reinsurance that will find its way into the AP ratio and the fee income, which I will have to put a loss reserve up against that drops through, but I hope that answered your question.

Sabra Purtill {BIO 1764408 <GO>}

Yes. And I would just add, the way I think the way people should think about it for the second half of the year is because we still have expenses in the travel business. Although we're not really getting any earned premium from right now. Combined with just the -- what I would call kind of the impact of the syndicate. I would look at the personal lines business has being kind of breakeven from an underwriting basis, obviously, depending on what happens with CATs for the portion that we retain, there might be some impact from that as well.

But then as you look going forward for 2021, hopefully, we'll have a travel business back, but the premium itself will be much smaller going forward for the personal lines business. And hopefully we'll have cut off the tail on underwriting volatility is really I think one of the things that I keep trying to remind people of is for personal lines, you can't really look at it is excluding CATs, because that is one of the major loss drivers of a personal lines book, particularly a heavily dominant homeowners book like we have in PCG. And then as we get to year end and we've rolled this portfolio or at least 75% of it. Fully into the syndicate the back of the envelope with respect to your question about capital, it's maybe roughly \$500 million of capital a little free up. So you will see that for your year-end RBC numbers.

Brian Meredith {BIO 3108204 <GO>}

Got it. Makes sense. I've got a couple of questions coming in and just wanted to get a clarification on my last question. Mark when we talked about, interest rates in effect on kind of combined ratios and stuff. I guess the question is as you think about the interest rate environment. Have you actually lowered your ROE expectations on underwriting?

Mark Lyons {BIO 21746221 <GO>}

On an explicit basis, no. And I think what it really implies is that, this is a great market right now and this is a market where you attempt to get within reasonable asset as much as you can out of it and don't limit yourself to -- and a line of business ex ROE, which you can actually get more, so that those areas are going to be pushed very hard, especially when you look at the elasticity between rate change and retention, so there's a lot of focus on that.

Brian Meredith {BIO 3108204 <GO>}

Okay, great. Next question, actually I got another one coming in here from the audience. In terms of emerging market strategy, how do you see your business in Latin America going forward? And are you contemplating any strategic alternatives there?

Mark Lyons {BIO 21746221 <GO>}

Well, it's kind of hard to comment on it not that large for us now. I think a lot of people, it's tempted to grow by going through the Brazilian reinsurance approach. AIG had gotten out a lot of Latin American areas the past regime before the current regime that in, that probably worthy of a revisit I'll leave it like that.

Brian Meredith {BIO 3108204 <GO>}

Got you. Okay, another one actually just came in with respect to your ceded reinsurance. Obviously, you've done a massive rework of your ceded reinsurance program really lower volatility should we -- given the reinsurance markets have kind of firmed up here too. Should we expect that that's going to be a bigger cost here going forward or could we start to see you guys retain more risk as your book kind of improves here?

Mark Lyons {BIO 21746221 <GO>}

A couple of -- great question. A couple of good views of that, first off on the dovetailing on Sabra's comments back about capital, with the structure changes on the high net worth business -- PCG business that on a forward basis should make the structure of our CAT program, maybe in the first program cheaper for AIG, because you don't have that kind of concentration aspect in there and it's in, but into a much lesser extent. And so on a go-forward basis everything else is being even for a minute, you could enjoy cheaper programs going forward.

Now on the second part of it any company should be reevaluating its reinsurance structure as a function of the -- not just the marketplace, but what the marketplace is doing to your view of the gross profitability, so to the extent that you want to retain more, because either the volatility you feel is better and the odds of making that profit are better. You may wind up ceding less. So -- and if you have demonstrated a material change in the book of business, that's audited by reinsurers and verified by reinsurers. You have a strong argument for actually ceding commission a positive change. So just look at it this way, in certain pockets there is an opportunity to grow on the front-end and possibly they grow because compoundedly, because of less session out the door.

Brian Meredith {BIO 3108204 <GO>}

Got you. Makes sense. Here's another one that could just came in I think it's a good one here. So, if we take a look at what your stock's trading right now obviously valuations really low. And I think we could probably to be part of that to the life insurance aspect of your business, right? If life insurers are trending pretty low, but even on some of the parts at least from my math, it's still looks really, really cheap here. The question then becomes, what kind of thought have you kind of put into maybe breaking up the GI and the life insurance businesses here, would AIG be better off actually having two separate businesses. Being two separate companies, publicly traded, whatever it is?

Mark Lyons {BIO 21746221 <GO>}

Yes, well I don't think that's not been in Management and the Board's mind. I mean that kind of thing always is thought of, going back to years and years and years ago before I

FINAL

joined the company. So, I mean with the tax reform, of course the DTA argument lessened, right, because of what you'd lose on foreign tax credits and NOLs, but it's still there. It's still a big number. Let alone the diversification loss and capital that you get, mostly from the rating agencies. What I think of diversification loss, I don't think of our internal capital, because that's inside baseball, what are your real binding constraints on capital, which is generally external, these rating agency forces and others. So it's the diversification change associated with their view of it. And the combination of those two things are still material, but I don't want you to think that it's not something that management would routinely strategically, think about. Sabra, anything you want to add?

Brian Meredith {BIO 3108204 <GO>}

Got it.

Sabra Purtill {BIO 1764408 <GO>}

Yes, look, I would just add that, those two reasons that are there still obviously significant for shareholders and would have a significant impact on shareholder value creation. But I would just note that strategically, there's no reason why our GI business needs to have an L&R business they have separate sales force and separate operations and the rest.

Brian Meredith {BIO 3108204 <GO>}

Got you. Makes sense. Let's see, next one, given where we are with current yields. I guess, it sounded like on the recent conference call that you're not expecting base spreads to kind of be greater than kind of -- greater contraction than original kind of forecast was which you kind of laid out maybe remind us, kind of, what's the impact?

Sabra Purtill {BIO 1764408 <GO>}

8 to 16.

Brian Meredith {BIO 3108204 <GO>}

Yes, the 8 to 16, is that, that's still what do you think, even though rates have come down even from those levels. I think when you originally gave us the 8 to 16. And then maybe on that topic. What kind of the outlook right now for sales and surrenders in the individual business?

Mark Lyons {BIO 21746221 <GO>}

Do you want to take that Sabra?

Sabra Purtill {BIO 1764408 <GO>}

Yes, I'll start with that. Yes on 8 to 16, that is up from where we are seeing the compression going back nine months ago or so, and obviously 100 basis point drop in the

Bloomberg Transcript

FINAL

10-year treasury over that time. But definitely put some pressure on the reinvestments. But the reason why it's still in the 8 to 16 range, I would say is that first of all credit spreads were a lot wider. So that has actually helped with some of that compression. Yes, we're largely an investment-grade corporate investor in the life and retirement. And the other aspect of it is that the portfolio duration of life and retirements like eight to nine years. So there is only a certain amount of the portfolio that's rolling off.

There's actually been and it will be interesting to see how this changes your last year we were seeing a lot more compression coming, because there is a really active tenders and calls on corporate debt in the second quarter just with all the market disruption we had, we didn't -- we had some other yield enhancement income, but it wasn't saw the same impact. So what I would kind of point people to is keep the eye on credit spreads, as much as you keep it on the risk free rate and keep an eye on what's happening with bond call activity. Because that -- those are really the key drivers that would impact the spreads.

And then obviously the other thing in life and retirement is really what happens with our alternatives. And that's been a tale of two cities so far, first quarter, we had negative impact on the hedge funds, but the private equity as you know is reported on a one quarter lag. So we had decent private equity returns in the first quarter. Second quarter, we had big gains on hedge funds, because of the market. But then we booked to losses on the private equity. So as you look into the third quarter, at least for private equity, we know what the market was at the end of June. So knock wood, that should be a favorable margin on the hedge funds. You tell me what the market looks like at 9/30, but so far this quarter, it looks pretty decent, and that's -- like I said, that's another component of the net investment income for life and retirement.

Brian Meredith {BIO 3108204 <GO>}

Makes sense. Okay, I know we're just about out of time here. And we've got other things on the meetings to get to. Let me ask just one quick other question here assumption reviews in third quarter, do you all with assumption grew in third quarter with your life insurance business and any reads on potential charges, there?

Mark Lyons {BIO 21746221 <GO>}

No, it's too early, Brian they're still go through that. But the only thing I could offer at this point is my comment on mortality where it wasn't severe enough of a change from the pricing assumptions that made us say, we got a -- let's front-load that into 2Q, so they're going through that now. So I don't have any antenna, I don't have cilia vibrating.

Brian Meredith {BIO 3108204 <GO>}

Got you.

Sabra Purtill {BIO 1764408 <GO>}

Yes and Brian. I would just add to that, because we have been asked for people about like a one factor sensitivity for the change in the interest rate on the DAC, and I know some of

our peers do that, but just remember that the assumption study looks at everything. And when you look at lower rates you're also generally looking at lower surrenders on the products that you have that's fixed rate oriented. So it's not just one factor sensitivity, we look at everything from mortality surrender activity policyholder behavior with respect to utilization of guarantees, which is one area that can surprise you people don't always behave economically and then obviously expenses market rate assumptions interest rate assumptions and the rest, so it's really soup to nuts.

Brian Meredith {BIO 3108204 <GO>}

All right, great.

Mark Lyons {BIO 21746221 <GO>}

And just to highlight also Brian, what Sabra talked about before on spreads. Everybody likes to focus on the 10-year bullet, right?

Brian Meredith {BIO 3108204 <GO>}

Okay.

Mark Lyons {BIO 21746221 <GO>}

And only one piece of the pie, right and only one piece of the pie. And one of our competitors this quarter, who does their assumption in the second quarter. I think went from a 3.75 to a 3.25 and we're already at 3.50. So on the bullet, if you will, that's just the risk free, there's already not much of a difference.

Brian Meredith {BIO 3108204 <GO>}

Makes sense. Makes sense. Mark, Sabra, so I really want to thank you all for your time. I apologize about all the technical difficulties here, but we got some good content good discussion and really, really appreciate your time. And everybody, just want you to stay safe, stay healthy and thanks for joining us.

Mark Lyons {BIO 21746221 <GO>}

Yes, I appreciate the invite, Brian. Thank you.

Sabra Purtill {BIO 1764408 <GO>}

Thank you.

Brian Meredith {BIO 3108204 <GO>}

Thanks all.

Sabra Purtill {BIO 1764408 <GO>}

Bye, everybody.

FINAL

This transcript may not be 100 percent accurate and may contain misspellings and other inaccuracies. This transcript is provided "as is", without express or implied warranties of any kind. Bloomberg retains all rights to this transcript and provides it solely for your personal, non-commercial use. Bloomberg, its suppliers and third-party agents shall have no liability for errors in this transcript or for lost profits, losses, or direct, indirect, incidental, consequential, special or punitive damages in connection with the furnishing, performance or use of such transcript. Neither the information nor any opinion expressed in this transcript constitutes a solicitation of the purchase or sale of securities or commodities. Any opinion expressed in the transcript does not necessarily reflect the views of Bloomberg LP. © COPYRIGHT 2022, BLOOMBERG LP. All rights reserved. Any reproduction, redistribution or retransmission is expressly prohibited.

Bloomberg Transcript